Posted by Michael Wonder on 07 Dec 2024
FDA grants fast track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer
3 December 2024 - Corbus Pharmaceuticals announced today that the US FDA has granted fast track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer.
CRB-701 (SYS6002) is a next generation antibody drug conjugate targeting Nectin-4 that contains a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE as the payload.
